Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing Purpose of reviewAntiretroviral (ARV) therapy costs in low-income and middle-income countries are major concerns, and lower doses of first-line treatment components, when possible, would save millions of dollars, which could be used to treat more people living with HIV.Recent findingsThe Encore-1 study, followed by a detailed pharmacokinetic analysis of efavirenz 400 versus 600 mg once daily, produced enough information for the most recent ARV treatment WHO guidelines to include efavirenz 400 mg among agents used for first-line treatment. However, data on efavirenz 400 mg plasma concentrations during pregnancy and when coadministered with rifampicin-containing antituberculosis (TB) treatment are not yet available as formal pharmacokinetic studies under these circumstances are ongoing.SummaryAlthough efavirenz at a daily dose of 400 mg once daily in combination with tenofovir disoproxil fumarate and emtricitabine has shown noninferiority to the approved 600 mg once-daily dose, large global uptake has been delayed by the lack of data on drug exposure during pregnancy and anti-TB treatment. Knowledge on efavirenz 400 mg exposure in these scenarios will arise in mid-late 2017. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/antiretroviral-dose-optimization-the-future-of-efavirenz-400-mg-dosing-p04UPrAUte

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000385
pmid
28570367
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewAntiretroviral (ARV) therapy costs in low-income and middle-income countries are major concerns, and lower doses of first-line treatment components, when possible, would save millions of dollars, which could be used to treat more people living with HIV.Recent findingsThe Encore-1 study, followed by a detailed pharmacokinetic analysis of efavirenz 400 versus 600 mg once daily, produced enough information for the most recent ARV treatment WHO guidelines to include efavirenz 400 mg among agents used for first-line treatment. However, data on efavirenz 400 mg plasma concentrations during pregnancy and when coadministered with rifampicin-containing antituberculosis (TB) treatment are not yet available as formal pharmacokinetic studies under these circumstances are ongoing.SummaryAlthough efavirenz at a daily dose of 400 mg once daily in combination with tenofovir disoproxil fumarate and emtricitabine has shown noninferiority to the approved 600 mg once-daily dose, large global uptake has been delayed by the lack of data on drug exposure during pregnancy and anti-TB treatment. Knowledge on efavirenz 400 mg exposure in these scenarios will arise in mid-late 2017.

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jul 1, 2017

References

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection
  • Initiation of antiretroviral therapy based on the 2015 WHO guidelines
  • Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
  • Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
  • Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
  • Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, noninferiority trial
  • Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
  • A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of Efavirenz (DMP-266) in combination with open-label zidovudine (ZDV) with Lamivudine (3TC) at 24 weeks (DMP 266–005)
  • Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries
  • Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, noninferiority trial
  • Efavirenz dose reduction in HIV-infected patients: a long-term follow-up
  • Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
  • Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race
  • Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
  • CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6∗9 and CYP2B6∗18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
  • Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine
  • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
  • Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naïve HIV-infected patients: results of the ENCORE1 study
  • Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
  • Does pregnancy affect the pharmacokinetics of efavirenz?
  • Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study